Zinc for prevention and treatment of the common cold

Nault, Daryl; Machingo, Taryn A; Shipper, Andrea G; Antiporta, Daniel A; Hamel, Candyce; Nourouzpour, Sahar; Konstantinidis, Menelaos; Phillips, Erica; Lipski, Elizabeth A; Wieland, L Susan

doi:10.1002/14651858.cd014914.pub2

Cited by 2 publications

(1 citation statement)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A statistically significant reduction in the incidence of exacerbations and an improvement in symptoms and quality of life of patients affected by chronic obstructive pulmonary disease (COPD) was evidenced in RCTs using a combination of propolis and N-acetylcysteine (NAC) [ 17 , 18 ]. A systematic review [ 19 ] examined data from 8526 patients who received zinc supplementation, demonstrating a reduction in the duration of the common cold. As evidenced by the scientific literature, the extract of Pelargonium sidoides may be an effective treatment for disorders affecting the respiratory tract, particularly in pediatric populations with acute non-streptococcal tonsillopharyngitis [ 20 , 21 ].…”

Section: Introductionmentioning

confidence: 99%

The Effectiveness of a Dietary Supplement with Honey, Propolis, Pelargonium sidoides Extract, and Zinc in Children Affected by Acute Tonsillopharyngitis: An Open, Randomized, and Controlled Trial

Cardinale,

Barattini,

Martinucci

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Physicians are currently finding products for pediatric respiratory diseases of viral etiology to reduce the inappropriate use of antibiotic therapy. This study evaluated PediaFlù (Pediatrica S.r.l.), a dietary supplement already on the market composed of honey, propolis, Pelargonium sidoides extract, and zinc (DSHPP), in children affected by acute tonsillopharyngitis (ATR). The open-label, randomized, and controlled study compared DSHPP + standard of care (SoC) versus SoC alone for six days. Children between 3 and 10 years with an ATR ≤ 48 h, a negative rapid test for beta-hemolytic Streptococcus, or a culture identification of nasal and/or pharyngeal exudates were included. A tonsillitis severity score (TSS) and the number of treatment failures (using ibuprofen or high-dose paracetamol as rescue medication) were the primary endpoints. DSHPP+ SoC showed better performance than SoC alone for TSS sub-scores: throat pain and erythema on day 6 (p < 0.001 and p < 0.05), swallowing (p < 0.01 on day 4), and TSS total score on days 4 and 6 (p < 0.05 and p < 0.001). Only one patient (SoC group) had treatment failure for ibuprofen administration. No adverse events were reported. DSHPP is an optimal adjuvant in the treatment of URTI and could potentially be useful in the daily clinical practice of paediatricians evaluating the correct antibiotic prescription.

show abstract

Section: Introductionmentioning

confidence: 99%